184 related articles for article (PubMed ID: 33242499)
21. Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.
Peng B; Hu Q; He R; Hou H; Lian D; Chen Y; Li H; Song L; Gao Y; Chen T; Zhang G; Li J
BMC Complement Med Ther; 2023 Feb; 23(1):62. PubMed ID: 36810081
[TBL] [Abstract][Full Text] [Related]
22. The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.
Sanchez CG; Molinski SV; Gongora R; Sosulski M; Fuselier T; MacKinnon SS; Mondal D; Lasky JA
Arthritis Rheumatol; 2018 Jan; 70(1):115-126. PubMed ID: 28940894
[TBL] [Abstract][Full Text] [Related]
23. Loss of the hyaluronan receptor RHAMM prevents constrictive artery wall remodeling.
Ma X; Pearce JD; Wilson DB; English WP; Edwards MS; Geary RL
J Vasc Surg; 2014 Mar; 59(3):804-13. PubMed ID: 23768790
[TBL] [Abstract][Full Text] [Related]
24. Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.
Park GT; Kwon YW; Lee TW; Kwon SG; Ko HC; Kim MB; Kim JH
Front Immunol; 2019; 10():2095. PubMed ID: 31552041
[TBL] [Abstract][Full Text] [Related]
25. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
[TBL] [Abstract][Full Text] [Related]
26. Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.
Akashi K; Saegusa J; Sendo S; Nishimura K; Okano T; Yagi K; Yanagisawa M; Emoto N; Morinobu A
Arthritis Res Ther; 2016 May; 18(1):113. PubMed ID: 27209208
[TBL] [Abstract][Full Text] [Related]
27. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
28. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses.
Wei J; Zhu H; Komura K; Lord G; Tomcik M; Wang W; Doniparthi S; Tamaki Z; Hinchcliff M; Distler JH; Varga J
Ann Rheum Dis; 2014 Feb; 73(2):446-54. PubMed ID: 23515440
[TBL] [Abstract][Full Text] [Related]
29. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
30. Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis.
Bahrami SB; Tolg C; Peart T; Symonette C; Veiseh M; Umoh JU; Holdsworth DW; McCarthy JB; Luyt LG; Bissell MJ; Yazdani A; Turley EA
Integr Biol (Camb); 2017 Mar; 9(3):223-237. PubMed ID: 28217782
[TBL] [Abstract][Full Text] [Related]
31. Toll-like receptor 2 (TLR2), transforming growth factor-β, hyaluronan (HA), and receptor for HA-mediated motility (RHAMM) are required for surfactant protein A-stimulated macrophage chemotaxis.
Foley JP; Lam D; Jiang H; Liao J; Cheong N; McDevitt TM; Zaman A; Wright JR; Savani RC
J Biol Chem; 2012 Oct; 287(44):37406-19. PubMed ID: 22948158
[TBL] [Abstract][Full Text] [Related]
32. Involvement of Disabled-2 on skin fibrosis in systemic sclerosis.
Mei X; Zhao H; Huang Y; Tang Y; Shi X; Pu W; Jiang S; Ma Y; Zhang Y; Bai L; Tu W; Zhao Y; Jin L; Wu W; Wang J; Liu Q
J Dermatol Sci; 2020 Jul; 99(1):44-52. PubMed ID: 32571632
[TBL] [Abstract][Full Text] [Related]
33. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
34. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Ruzehaji N; Frantz C; Ponsoye M; Avouac J; Pezet S; Guilbert T; Luccarini JM; Broqua P; Junien JL; Allanore Y
Ann Rheum Dis; 2016 Dec; 75(12):2175-2183. PubMed ID: 26961294
[TBL] [Abstract][Full Text] [Related]
35. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?
Wei J; Melichian D; Komura K; Hinchcliff M; Lam AP; Lafyatis R; Gottardi CJ; MacDougald OA; Varga J
Arthritis Rheum; 2011 Jun; 63(6):1707-17. PubMed ID: 21370225
[TBL] [Abstract][Full Text] [Related]
36. Activation of pregnane X receptor inhibits experimental dermal fibrosis.
Beyer C; Skapenko A; Distler A; Dees C; Reichert H; Munoz L; Leipe J; Schulze-Koops H; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2013 Apr; 72(4):621-5. PubMed ID: 23291432
[TBL] [Abstract][Full Text] [Related]
37. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
38. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?
Kokot A; Sindrilaru A; Schiller M; Sunderkötter C; Kerkhoff C; Eckes B; Scharffetter-Kochanek K; Luger TA; Böhm M
Arthritis Rheum; 2009 Feb; 60(2):592-603. PubMed ID: 19180474
[TBL] [Abstract][Full Text] [Related]
39. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
40. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
Zhu L; Song Y; Li M
J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
